Tyzeka, Sebivo(telbivudine)
Sebivo, Tyzeka (telbivudine) is a small molecule pharmaceutical. Telbivudine was first approved as Tyzeka on 2006-10-25. It is used to treat chronic hepatitis b and hepatitis b in the USA. It has been approved in Europe to treat chronic hepatitis b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis b | — | D006509 | — |
| chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 2 | 10 | 12 | — | 25 |
| Hepatitis b | D006509 | — | — | — | 2 | 8 | 3 | — | 13 |
| Hepatitis | D006505 | — | K75.9 | — | 1 | 4 | 2 | — | 7 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | 4 | 1 | — | 6 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | 3 | 2 | — | 5 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | 1 | — | 2 |
| Biliary liver cirrhosis | D008105 | — | K74.3 | — | — | — | 1 | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b virus | D006515 | — | — | — | — | 1 | — | — | 1 |
| Patient compliance | D010349 | — | — | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Telbivudine |
| INN | telbivudine |
| Description | Telbivudine is a pyrimidine 2'-deoxyribonucleoside that is the L-enantiomer of thymine. A synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It has a role as an antiviral drug and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is functionally related to a thymine. It is an enantiomer of a thymidine. |
| Classification | Small molecule |
| Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 3424-98-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL374731 |
| ChEBI ID | 63624 |
| PubChem CID | 159269 |
| DrugBank | DB01265 |
| UNII ID | 2OC4HKD3SF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,768 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,340 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use